Novanta Inc is expected to report Q3 2026 revenue of approximately $301.02 million and adjusted EPS of $0.97, while the current share price of $147.49 implies substantial upside toward the $194.50 consensus price target.
Investors are intensely focused on the integration of Riverpoint Medical, the company's largest-ever acquisition, and its contribution to expanding medical market exposure to 60% of total sales. The quarter's results are expected to reflect a reported revenue surge of over 21% YoY, driven by acquisitions, alongside organic growth guidance of 7% to 9%.
Analysts will also scrutinize the progress of manufacturing transformation initiatives, including planned factory closures aimed at optimizing operational efficiency and gross margins.